Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02654132 · OUTCOME

Overall Survival (OS)

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) · Source last updated 2022-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
From randomization to death (up to approximately 52 months)

What was measured

OS is the time from randomization to the date of death from any cause. The survival time for participants who had not died was censored at the last known alive date. OS was censored at the date of randomization for subjects who were randomized but had no follow-up.

Analysis population: All randomized participants

Groups in this outcome

E-Pd Cohort

Elotuzumab + Pomalidomide + Dexamethasone

Pd Cohort

Pomalidomide + Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
E-Pd Cohort60
Pd Cohort57

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
E-Pd Cohort29.80Not reported22.8745.67Not reported
Pd Cohort17.41Not reported13.8327.70Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.37
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.93
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.0217
    param Type
    Hazard Ratio (HR)
    param Value
    0.59
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Lower Limit
    0.37
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.93
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.0217
    param Type
    Hazard Ratio (HR)
    param Value
    0.59
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        22.87
        upper Limit
        45.67
        value
        29.80
      2. group Id
        OG001
        lower Limit
        13.83
        upper Limit
        27.70
        value
        17.41
denoms
  1. counts
    1. group Id
      OG000
      value
      60
    2. group Id
      OG001
      value
      57
    units
    Participants
description
OS is the time from randomization to the date of death from any cause. The survival time for participants who had not died was censored at the last known alive date. OS was censored at the date of randomization for subjects who were randomized but had no follow-up.
dispersion Type
95% Confidence Interval
groups
  1. description
    Elotuzumab + Pomalidomide + Dexamethasone
    id
    OG000
    title
    E-Pd Cohort
  2. description
    Pomalidomide + Dexamethasone
    id
    OG001
    title
    Pd Cohort
param Type
MEDIAN
population Description
All randomized participants
reporting Status
POSTED
time Frame
From randomization to death (up to approximately 52 months)
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice